Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
85
Active:28
Completed:45
Trial Phases
4 Phases
Phase 1:38
Phase 2:16
Phase 3:27
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (84 trials with phase data)• Click on a phase to view related trials
Phase 1
38 (45.2%)Phase 3
27 (32.1%)Phase 2
16 (19.0%)Not Applicable
3 (3.6%)Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: GP MDI 28.8 μgDrug: GP MDI 14.4 μgDrug: GP MDI 7.2 μgDrug: Placebo MDI
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 1077
- Registration Number
- NCT03358147
- Locations
- 🇺🇸
Research Site, Greenfield, Wisconsin, United States
A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03311373
- Locations
- 🇺🇸
Pearl Investigative Site, Baltimore, Maryland, United States
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: GFF MDI (PT003)Drug: BGF MDI (PT010)Drug: BFF MDI (PT009)
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 416
- Registration Number
- NCT03262012
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03256552
- Locations
- 🇯🇵
Pearl Investigative Site, Toshima-ku, Tokyo-To, Japan
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03250182
- Locations
- 🇺🇸
Research Site, Clearwater, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found